PT - JOURNAL ARTICLE AU - , AU - Bilinski, Alyssa AU - Birger, Ruthie AU - Burn, Samantha AU - Chitwood, Melanie AU - Clarke-Deelder, Emma AU - Copple, Tyler AU - Eaton, Jeffrey AU - Ehrlich, Hanna AU - Erlendsdottir, Margret AU - Eshghi, Soheil AU - Farid, Monica AU - Fitzpatrick, Meagan AU - Giardina, John AU - Gonsalves, Gregg AU - Hsieh, Yuli Lily AU - Iloglu, Suzan AU - Kao, Yu-Han AU - MacKay, Evan AU - Menzies, Nick AU - Mulaney, Bianca AU - Paltiel, David AU - Perniciaro, Stephanie AU - Phillips, Maile AU - Rich, Katherine AU - Salomon, Joshua A AU - Sherak, Raphael AU - Shioda, Kayoko AU - Swartwood, Nicole AU - Testa, Christian AU - Thornhill, Thomas AU - White, Elizabeth AU - Williamson, Anne AU - York, Anna AU - Zhu, Jinyi AU - Zhu, Lin TI - Defining high-value information for COVID-19 decision-making AID - 10.1101/2020.04.06.20052506 DP - 2020 Jan 01 TA - medRxiv PG - 2020.04.06.20052506 4099 - http://medrxiv.org/content/early/2020/04/08/2020.04.06.20052506.short 4100 - http://medrxiv.org/content/early/2020/04/08/2020.04.06.20052506.full AB - Initial projections from the first generation of COVID-19 models focused public attention on worst-case scenarios in the absence of decisive policy action. These underscored the imperative for strong and immediate measures to slow the spread of infection. In the coming weeks, however, as policymakers continue enlisting models to inform decisions on COVID-19, answers to the most difficult and pressing policy questions will be much more sensitive to underlying uncertainties. In this study, we demonstrate a model-based approach to assessing the potential value of reducing critical uncertainties most salient to COVID-19 decision-making and discuss priorities for acquiring new data to reduce these uncertainties. We demonstrate how information about the impact of non-pharmaceutical interventions could narrow prediction intervals around hospitalizations over the next few weeks, while information about the prevalence of undetected cases could narrow prediction intervals around the timing and height of the peak of the epidemic.Competing Interest StatementThe authors have declared no competing interest.Funding StatementC-SPEC does not have institutional funding. C-SPEC member funding is provided in its authorship list.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesModel code is available on GitHub.